The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Have mentioned previously that I like many others were waiting for funding to be sorted prior to adding to existing holding, as I'm sure many will be aware the normal aim script is fund raise, sp drop over next 2-3 weeks (sometimes because funders have hedged)
a few panic sell, others add, normally at some point in future sp surges upwards as good news arrives, funders would have been aware of this expected news hence their investment...
It's not rocket science, with nice in the bag, cash in bank and global distributors being set up, what's not to like,
I have no issue with sp drop, just adding opportunities for all that are so inclined.
Dave
The only reason I can see for db doing this type of funding is to cover the short term funding issue with minimal dilution, expecting sales to progress over the next few months sufficiently to support the company, surely if you buy into the company, products and future you would sit tight and wait for things to unfold, otherwise, you would have sold at the recent highs and moved on hence the only reason I can find for the recent negative posting is to be as disruptive as possible,
Remember the great pop eye, bought at 9p sold at 13p and called us all clueless fools for not taking the quick profit, well now a few weeks later we are at 25p with some moaning incessantly.....
Yes we went to 48p,
If you don't like where company is at you should have sold....
Don't go blaming db....
He doesn't control your sell button,
Try having a bit of belief in company for a change. Oh and a bit of patience....
Dave
Doesn't really matter if you bought in today at 30p or 34p, even if sp drops to 20's,
The one major obstacle of funding is now secure, with NICE recommendation confirmed I would presume sales will follow, as db advised previously this is a slow process and will build up a head of steam, the golden ticket is repeat assay orders which automatically come with device take up and with multiple global distributors coming on board we should develop a steady flow of new business, great time to be here after all the dark days and delighted for all the holders that stuck by genedrive, good luck all, enjoy the journey whichever station you get off at I would hope plenty more will be looking to get on board.
Dave
Think it’s a good deal all round and well done DB and Genedrive,
I’m sure many will add now with “going concern” dealt with, approvals in place, what’s not to like…
Hopefully we can all have a more relaxed journey going forward, onwards and upwards with less bumps in the road.
Dave
It's like changeover day at the holiday camp,
Some leaving happy with there time and new one arriving full of optimism looking forward to their stay,
Hope the sun shines...
I have stated previously that I thought raise was on way, if fact I expected it a few weeks or so ago so what do I know !!
as there have been multiple opportunities and none taken I can only presume bod have something lined up as/when nice guidance is received....
Private placement perhaps, have to be honest haven't got a clue anymore 2nd and third guessing myself....
What I do know is we are not at 9p anymore and that's a pretty good feeling, days like today don't seem to matter quite as much.
Dave
Expert trader,
Sorry to pull you up but
Audited financial results of 21st November 2022
Rns of same day contradict your statement....
"I dont think we'l see a raise anytime soon either and most know that now. They said IF there is a raise it will be late 2023 so i dont think we will have one yet if ever. And i think maybe never because firstly they will look for alternatives IF needs be and secondly we may have huge sales by then"
Russ Shaw, chief financial officer for Genedrive stated...
"Following the equity fund raise which completed in October 2021 the Company has a cash runway to the end of the June 2023 financial year. We are confident in gaining commercial traction and securing significant revenues, but due to the time required to achieve this, we will require additional funding in our 2023 financial year. As described in the accounting policies, we continue to adopt a going concern basis for the preparation of the accounts, but the above condition represents a material uncertainty that may cast significant doubt on the Group and Company's ability to continue as a going concern.
Russ Shaw
Chief Financial Officer"
Appears some significant strength to sp rises over past 7 days, not seen this for a long time...
Have a lower holding than desired due to being stung so many times in past....
With news flow on new distributors plus Lloyds very useful correspondence of late and with significant news to come, alls looking positive.
Good luck everyone, hope this is our time
Some strange posts last few days,
Genedrive is not sinking like the titanic it is in fact on the cusp of great things with first to market diagnostic test,
Also is quite clear (as informed by company rns) fund raise required, question no one knows the answer to is when and at what sp,
We can all guess and discuss possibilities but to talk down company progress is absurd..
As long as we don't become distressed and forced to raise at a lower than desired sp that's fine and in the hands of the bod, one thing I am certain about is we will be able to raise regardless, this has not always been a dead cert previously, now it is....
One possibility and only my musings is fda submission is waiting on nice report end of March, if these come one after the other I'm pretty certain we could raise or partner for funding at higher sp, I presume many like myself are happy to add at higher sp once financials are sorted or of course at a lower sp if distressed raise....
We all have the choice when to press the buy/sell button, it's a personal choice and no one else's business but let's not talk down the company because of our personal choices,
Has been a great few months with a bright future on the horizon.
Dave
System,
I find you most enthusiastic and entertaining, quite harmless however you didn't cover yourself in glory by selling half your holding at 8p and buying back in at 30p,
Your prediction are most helpful as usually the sp does the opposite !!
Try and keep away from the insults (both ways) Jay along with others has provided lots of useful info...
All the best, hope it comes good for you and the same for all of us...
Hoping the bickering stops and the more informed posters (of which I am not) can offer more technical/scientific insight on the road forward, potential new products, timeline on stroke test etc
I'm surprised a raise has not been done over past couple of weeks while sp was on the up,
Unsure as to why...
Possibles I can see and would welcome any views/opinions..
Company awaiting further news to drive sp significantly higher.
Eg
1. fda application update
2. 31st March nice guidance,
3. Possible early nice notification 21st feb..
4. partnership in negotiation...
I'm sure that there are many like myself whom would add further once funding is resolved even at a higher sp
Even with difficult capital market conditions I'm sure Genedrive could raise given the significant nice news we had so can only presume they do not wish to currently do so.....thoughts ?
Additionally,
It's easier to look at the facts as stated rather than superstition,
I'm presuming the companies own declaration below would mean they are not expecting significant take up in next 3 months otherwise why state it in rns.
"We are confident in gaining commercial traction and securing significant revenues, but due to the time required to achieve this, we will require additional funding in our 2023"
As it's now February and funded to June,
With June being 4 month away, it's pretty conclusive (but not absolute) that a 3 month timeline is unrealistic.
As bankruptstock mentioned,
Nhs May take up to 12 months to purchase,
However once it does there is a repeat revenue stream of £4m per year just for the Uk just for one product....
This is confirmed by the below statement.
"PALOH study lead, Professor Bill Newman, Consultant in Genomic Medicine at MFT and Professor of Translational Genomic Medicine at The University of Manchester, said: “We are delighted that NICE has conditionally recommended the use of the test, which will be used in routine clinical practice in maternity settings across the country."
Additionally has also been stated in bmj
"The NICE recommendations apply directly to England and Wales, but are often adopted more widely. "
Don't think it's being overly presumptuous that "adopted more widely" means the rest of the world.
The long term revenue streams for Genedrive products is immense,
Just a few minor hurdles on the way and we are there.
Dave
Bankruptstock…
Talk about putting a negative spin on great great news... in fact the best news any of us could have hoped for....
THE only thing holding the Genedrive sp back is future funding, once this is addressed which it will be it's onwards and upwards,
The short term question is at what sp and what discount, it is very feasible that we could raise at 40p/30p/25p/20p/15p.. dependant upon news flow and timing, none of us know that's for sure....
It's one of those rare occasions when I don't think it really matters as long as it's a done deal.... as I mentioned the other day, I believe 70p ish is possible later this year after raise...
Buy/hold/trade do what you will, don't think any holder will lose out long term, just a bit of short term pain.
Dave
Multiple options are on the table here,
Raise
Convertible bond
Debt finance
Partnership with upfront fee etc etc
Just want bod to be ahead of the curve on this before hands get tied and us pi's get shafted...
Once sorted at whatever the sp is at that time, tomorrow, next week, next month, will likely see a significant bounce.